Low-Density LRP1 As A Regulator of Tau Protein Spread
Tech ID: 31949 / UC Case 2020-709-0
The spread of protein aggregates during disease progression is a common theme underlying many neurodegenerative diseases. Progression of these diseases is characterized by the spread and deposition of protein aggregates that correlate with clinical severity. The protein tau plays a central role in the pathogenesis of a variety of neurodegenerative diseases, such as Alzheimer’s disease, and the spread of tau aggregation throughout the brain correlates with cognitive decline in patients.
Researchers at the University of California, Santa Barbara have identified the protein LRP1 as a cellular endocytosis receptor for the protein tau. The low-density lipoprotein receptor-related protein 1 (LRP1) controls tau endocytosis and its subsequent spreading. The identification of LRP1 as a critical determinant for tau spread defines a novel drug target for diseases of tau spread or aggregation. This technology also presents a therapeutically compelling discovery of how the receptor mediates tau uptake in conjunction with its other relevant interactions, such as with ApoE.
- Reduces tau spread and aggregation
- Improves patient resistance against neurodegenerative diseases